PBM PSYENCE BIOMEDICAL LTD. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1985062 · Fiscal year ends 03/31
Financial factors as of 2025-03-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q2*2025-09-30 | 2025Q2*2024-09-30 | 2024Q2*2023-09-30 |
|---|---|---|---|
| Income statement | |||
| Revenue | — | — | — |
| R&D expense | $357,444 | $265,626 | — |
| SG&A expense | $217,225 | $243,044 | -$16,123 |
| Interest expense | $2,753 | $3,715 | $27,936 |
| Pretax income | -$1.50M | -$1.16M | — |
| Net income | -$753,254 | $141,473 | -$309,682 |
| EPS (basic) | -0.51 | 4.07 | — |
| EPS (diluted) | -0.51 | 4.07 | — |
| Weighted avg. shares (diluted) | 1.48M | 34,731 | — |
| Balance sheet | |||
| Cash & equivalents | $7.15M | $1.93M | $605,480 |
| Current assets | $7.63M | $2.24M | — |
| PP&E, netmay include right-of-use assets (IFRS) | $8,690 | $10,126 | — |
| Total assets | $12.81M | $2.25M | — |
| Total liabilities | $943,068 | $3.51M | — |
| Shareholders' equity | $11.87M | -$1.26M | -$982,671 |
| Shares outstanding | — | 605,789 | — |
| Cash flow statement | |||
| Operating cash flow | — | — | — |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.